Pennsylvania Consortium: Clinical Database
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Amyotrophic Lateral Sclerosis
- 发起方
- Drexel University College of Medicine
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- None Specified
- 状态
- 终止
- 最后更新
- 9年前
概览
简要总结
In order to streamline disease research in ALS and other motor neuron diseases, we have joined a consortium of clinical centers (Hershey and University of Pittsburgh) who will collaborate on clinical and basic research projects. As part of this collaboration, de-identified clinical data from subjects at each institution will be entered into a joint database kindly provided and maintained by the ALS Hope Foundation. This database is password protected and contains only de-identified information. In addition to clinical data, any research specimens that are available through IRB approved tissue collections will be linked to the subject so that the collaborating investigators can share samples and have the maximum information. This will enhance the usefulness of each specimen.
Once established, the database will provide a resource in which clinical data on a large number of patients along with tissue (blood, urine, muscle, csf, and autopsy) samples will be readily available. This will expedite research by circumventing the delays in collecting specimens prospectively and increase the number of specimens available by allowing the collaborating researchers access to each others specimens. In each case there will be a formal request placed to use specimens that are at the other institutions. These specimens will be used for research in the ALS Center of Hope at the Drexel University College of Medicine and shared with outside investigators with valid IRB approved protocols.
研究者
入排标准
入选标准
- •Clinical data on patients with motor neuron diseases (ALS, PLS, Bulbar Palsy) and related disorders
排除标准
- •Any patient without a motor neuron disease or related disorder
结局指标
主要结局
None Specified
时间窗: None Specified
This database is intended to increase the efficiency of other IRB approved protocols by increasing accessibility of information and biological samples from the ALS cohort. No direct outcome measures have been specified for the creation of the database.